Overcoming Bioanalytical Challenges in Anti-Drug Antibody Detection for ADCs, Upcoming Webinar Hosted by Xtalks

In this free webinar, gain insight into different alternatives to mitigate the presence of pre-existing antibodies for method validation and cut-point determination. Attendees will learn how to approach pre-existing antibodies based on their incidence. The featured speaker will discuss how the presence of pre-existing antibodies can impact the different testing tiers and requirements for testing tiers.

TORONTO, Sept. 4, 2025 /PRNewswire/ -- Antibody-drug conjugates (ADCs) and other next-generation drug modalities are unlocking new treatment possibilities. However, their unique designs can also create unexpected challenges for bioanalytical teams.

In this webinar, attendees will hear the story of a real-world ADC case study: a humanized single-chain antibody linked to a bacterial toxin protein. The team selected a bridging anti-drug antibody (ADA) assay based on the MSD platform, with the ADC biotinylated and conjugated to Sulfo-TAG, and introduced an acid dissociation step to improve drug tolerance.

Then came a surprising discovery: about 90% of naïve donor samples contained widely varying levels of pre-existing antibodies. A few low-signal samples were used to create a negative control pool, and the initial method design included screening, confirmatory, domain specificity and titer tiers.

Because most people have been exposed to the bacterial toxin during their lifetime, it was quickly confirmed that the majority of pre-existing antibodies targeted the toxin component of the ADC. This insight directly influenced the selection of testing tiers used in the method. Changes in titer values were then used as a key indicator to determine whether treatment-boosted anti-ADC antibodies had developed over the course of treatment.

Since cut-point determination requires at least 50 samples expected to be negative, finding a sufficient number of true negative samples proved challenging. Several strategies were evaluated during method development, and one approach was ultimately selected to establish the ADA method cut-points needed for the testing cascade.

During the webinar, the featured speaker will discuss how this mitigation strategy produced reliable cut-points and strong assay sensitivity for ADA detection.

With this approach, the validated method was applied to Phase III study samples. As expected, most baseline samples were positive for pre-existing antibodies, particularly against the toxin domain. Despite this, the assay was able to identify treatment-boosted ADA and determine their domain specificity.

Register for this webinar to learn how to adapt ADA assay design to the unique bioanalytical challenges of ADCs. Topics will include practical strategies for dealing with high pre-existing antibody rates and lessons learned from real clinical sample analysis.

Join Martin Roberge, PhD, Director, Development & Innovation, Bioanalytical Center of Excellence, Cerba Research, for the live webinar on Wednesday, September 24, 2025, at 10am EDT (4pm CEST/EU-Central).

For more information, or to register for this event, visit Overcoming Bioanalytical Challenges in Anti-Drug Antibody Detection for ADCs.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit www.xtalks.com
For information about hosting a webinar, visit www.xtalks.com/why-host-a-webinar/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]

SOURCE Xtalks